A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.

Publication Type:

Journal Article

Source:

Journal of hematology & oncology, Volume 5, p.71 (2012)

Keywords:

Clinical Research Division, December 2012

Abstract:

ABSTRACT: